European Heart Journal

• 

  Publication Venue For

  • Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial..  38:2813-2822. 2017
  • Anticoagulation in coronary intervention..  37:3376-3385. 2016
  • Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease..  37:1993-2001. 2016
  • Lessons learned and a look to the future: The chronic ischemic heart disease (CICD) pilot registry.  37:161-163. 2016
  • Current worldwide nuclear cardiology practices andradiationexposure: Results from the 65country IAEA nuclear cardiology protocols cross-sectional study (INCAPS).  36:1689-1696. 2015
  • Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.  36:288-296. 2015
  • Prognostic implication of the new peri-PCI (type 4a) myocardial infarction definition according to the third universal definition of myocardial infarction in patients with NSTE ACS.  35:138-138. 2014
  • Relationship between diabetes, race, obesity and outcomes in patients with acute coronary syndrome: a pool analysis from randomized trials.  34:787-787. 2013
  • Contributions of peak expiratory flow to assessment of acute decompensated heart failure: insights from ASCEND-HF.  32:964-964. 2011
  • Gender paradox: higher incidence but lower one-year mortality with bleeding among women compared with men following fibrinolysis for acute ST-elevation myocardial infarction.  32:166-166. 2011
  • The independent prognostic value of hyponatremia in a cohort of heart failure patients: analysis from the Duke databank for cardiovascular disease.  32:134-134. 2011
  • Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the APEX-AMI trial.  32:872-872. 2011
  • Early in-ospital worsening heart failure predicts adverse outcome in patients.  30:719-719. 2009
  • Echocardiographic predictors of long-term survival in adults with pulmonary hypertension.  30:115-115. 2009
  • Effects of the new vasodilator relaxin for the treatment of patients with acute heart failure and normal to elevated blood pressure: results of a phase 2b study (Pre-RELAX-AHF).  30:424-425. 2009
  • Impact of anemia in patients with pulmonary hypertension.  30:260-260. 2009
  • Impact of incidentally discovered patent foramen ovale and its operative repair on long-term survival.  30:6-6. 2009
  • Improved pulmonary insufficiency with inhaled vasodilator assessed by cardiac magnetic resonance imaging.  30:811-811. 2009
  • Increased symptom-improvement with the novel vasodilator, relaxin, in Acute Heart Failure (AHF) patients with elevated blood pressure. Results from the Pre-RELAX-AHF study.  30:164-164. 2009
  • Novel intravascular defibrillator (InnerPulse PICD): defibrillation thresholds of PICD compared to Medtronic ICD in a canine model.  30:276-276. 2009
  • Patient-reported dyspnea in acute heart failure trials. Use of the Likert and the visual analog scales in the pre-RELAX AHF study.  30:445-446. 2009
  • Prevalence & prognostic importance of micro-& macro-albuminuria in heart failure- an analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme.  30:876-876. 2009
  • Pulmonary vasodilator challenge predicts survival in patients with various etiologies of pulmonary hypertension.  30:899-900. 2009
  • Racial disparities in survival in patients with pulmonary hypertension.  30:513-513. 2009
  • Time to treatment and vasodilator efficacy in acute heart failure: Results from the Pre-RELAX-AHF study.  30:424-424. 2009
  • Worsening renal function in acute heart failure: change in BP and effects of relaxin.  30:1020-1021. 2009
  • Acute severe hypertension has high morbidity, mortality, and readmission rates: results from the STAT registry.  29:513-513. 2008
  • An RNA aptamer inhibiting factor IXa and its complementary oligonucleotide antidote.  29:328-328. 2008
  • Cognitive function and anticoagulation control in patients with atrial fibrillation.  29:258-258. 2008
  • Endoscopic vein harvesting is a strong independent predictor of vein graft failure in patients undergoing coronary artery bypass graft surgery.  29:284-285. 2008
  • Has the frequency of bleeding improved over time for patients presenting with an acute coronary syndrome? The GRACE Registry.  29:326-326. 2008
  • Impact of incidentally discovered patent foramen ovale and its repair on perioperative outcomes in 13,260 cardiothoracic surgery patients.  29:124-124. 2008
  • Late recanalization of infarct related artery has no impact on clinical outcomes regardless of ejection fraction: Results from the Occluded Artery Trial (OAT).  29:679-679. 2008
  • Mechanical complications are uncommon in STEMI treated with primary-PCI: insights from APEX-AMI.  29:137-138. 2008
  • Mortality after cardiogenic shock remains high in ST-elevation myocardial infarction treated with primary PCI: insights from APEX AMI.  29:447-447. 2008
  • Prevalence and predictors of dyssynchrony as determined by gated SPECT perfusion imaging in patients with left ventricular dysfunction.  29:5-5. 2008
  • Surgical treatment of anomalous coronary arteries passing between the great vessels in older adults may not improve survival.  29:7-7. 2008
  • Triple combination Ezetimibe/Simvastatin plus extended release Niacin therapy improves ratios of ApoB/ApoA-I containing lipoproteins in hyperlipidemia patients.  29:345-346. 2008
  • Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative..  29:1103-1109. 2008
  • Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study..  29:1127-1135. 2008
  • Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy..  29:871-879. 2008
  • Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb..  29:880-887. 2008
  • Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study..  29:748-756. 2008
  • Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go..  29:609-617. 2008
  • Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment..  29:315-323. 2008
  • Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI..  28:2850-2857. 2007
  • Cardiovascular disease on a global scale: defining the path forward for research and practice..  28:2678-2684. 2007
  • A new model for predicting mortality in acute ST elevation myocardial infarction treated with primary PCI: results from the APEX AMI trial.  28:59-59. 2007
  • Adverse outcomes in fibrinolytic-based facilitated PCI: insights from the ASSENT-4 PCI electrocardiographic substudy.  28:59-59. 2007
  • Atrial fibrillation is associated with worse outcomes in ST elevation and non ST elevation acute coronary syndromes.  28:259-260. 2007
  • Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial.  28:516-516. 2007
  • Can we predict non-fatal cardiovascular events in acute coronary syndrome? The Global Registry of Acute Coronary Events.  28:689-689. 2007
  • Comparison of outcomes between patients undergoing percutaneous coronary stent implantation with eptifibatide and abciximab: an analysis using propensity score methods.  28:184-184. 2007
  • Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women..  28:2064-2069. 2007
  • Outcomes for stenting in single and multivessel coronary artery disease using established and novel paclitaxel eluting stent platforms: COSTAR II.  28:577-577. 2007
  • Predictors of angiographic success and relationship to clinical outcomes during primary PCI for ST elevation acute myocardial infarction: insights from APEX-AMI.  28:660-660. 2007
  • Short-term outcomes are at least as good with drug eluting vs. bare metal stents: insights from APEX AMI.  28:9-9. 2007
  • Similar association between age and outcomes in high-risk ACS patients treated with enoxaparin or unfractionated heparin.  28:218-218. 2007
  • The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial.  28:187-187. 2007
  • Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab.  28:384-385. 2007
  • Retinal vessel diameter and cardiovascular mortality: pooled data analysis from two older populations..  28:1984-1992. 2007
  • Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes..  28:1598-1660. 2007
  • Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction..  28:1709-1716. 2007
  • Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes..  28:1193-1204. 2007
  • Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study..  28:1109-1116. 2007
  • Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial..  28:1079-1084. 2007
  • Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry..  28:980-988. 2007
  • Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial..  28:685-691. 2007
  • Ruminating on OAT: is the case closed?.  28:531-532. 2007
  • The cost of implantable defibrillators: how the perception of reality depends on perspective.  28:386-387. 2007
  • Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials..  28:425-432. 2007
  • The high cost of implantable defibrillators..  28:388-391. 2007
  • The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction..  28:415-424. 2007
  • Diabetes mellitus and insulin therapy in infective endocarditis..  28:3-4. 2007
  • Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial..  27:3027-3032. 2006
  • Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire?.  27:2737-2739. 2006
  • Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes..  27:2956-2961. 2006
  • Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study..  27:2516-2523. 2006
  • Glucose, insulin, and acute myocardial infarction: Reply [4].  27:2142-2143. 2006
  • A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study..  27:1530-1538. 2006
  • International variation in invasive care of the elderly with acute coronary syndromes..  27:1558-1564. 2006
  • Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study..  27:1289-1297. 2006
  • Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..  27:1447-1458. 2006
  • Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial..  27:1198-1206. 2006
  • Persistent and reversible cardiac dysfunction among amateur marathon runners..  27:1079-1084. 2006
  • Aborted myocardial infarction: a new target for reperfusion therapy..  27:901-904. 2006
  • Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes..  27:527-533. 2006
  • Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction..  27:419-426. 2006
  • How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts..  27:323-329. 2006
  • Predictors of mortality and morbidity in patients with chronic heart failure..  27:65-75. 2006
  • Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention..  26:2396-2403. 2005
  • Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes..  26:2106-2113. 2005
  • Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry..  26:2114-2119. 2005
  • Moving proximally through the intersection between the process and the content of care in ST-elevation myocardial infarction..  26:1937-1938. 2005
  • Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial..  26:1964-1970. 2005
  • A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy..  26:1726-1733. 2005
  • Simplifying risk stratification in non-ST-segment elevation acute coronary syndromes.  26:431-431. 2005
  • Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies..  26:1461-1474. 2005
  • Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial..  26:1506-1512. 2005
  • Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry..  26:1063-1069. 2005
  • The effect of intra-aortic balloon counterpulsation on left ventricular functional recovery early after acute myocardial infarction: a randomized experimental magnetic resonance imaging study..  26:1235-1241. 2005
  • Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction..  26:667-674. 2005
  • The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort..  26:421-422. 2005
  • Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality..  26:288-297. 2005
  • Assessing risk in FRISC..  26:103-104. 2005
  • Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials..  26:128-136. 2005
  • An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry..  25:1911-1919. 2004
  • Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..  25:1920-1926. 2004
  • Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial..  25:1688-1694. 2004
  • Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS..  25:1494-1501. 2004
  • Persistent diastolic dysfunction despite complete systolic functional recovery after reperfused acute myocardial infarction demonstrated by tagged magnetic resonance imaging..  25:1419-1427. 2004
  • Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes..  25:313-321. 2004
  • International variation in the use of evidence-based medicines for acute coronary syndromes..  24:2133-2141. 2003
  • Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry..  24:1763-1770. 2003
  • Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial..  24:1807-1814. 2003
  • Early hospital discharge after uncomplicated myocardial infarction: are further improvements possible?.  24:1613-1615. 2003
  • International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2..  24:1640-1650. 2003
  • From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)..  24:1414-1424. 2003
  • ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction..  24:1515-1522. 2003
  • The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2..  24:1024-1034. 2003
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study..  24:897-908. 2003
  • Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?.  24:522-531. 2003
  • P2275 Plasma homocystein levels independently correlate with angiographic extension of coronary artery disease.  24:436-436. 2003
  • Cardiac markers in acute coronary syndromes-refining our knowledge..  24:136-137. 2003
  • Predictors of 90-day outcome in patients stabilized after acute coronary syndromes..  24:172-181. 2003
  • Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making..  24:182-189. 2003
  • Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes..  23:1538-1545. 2002
  • Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion..  23:1449-1455. 2002
  • Determinants of matrix metalloproteinases plasma concentration and activity in premature coronary atherosclerosis.  23:135-135. 2002
  • Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy..  23:1202-1212. 2002
  • Effect of simvastatin on endothelial damage markers and clinical outcomes in acute coronary syndromes.  23:419-419. 2002
  • Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial..  23:1102-1111. 2002
  • Assessment of myocardial viability by cardiovascular magnetic resonance imaging..  23:602-619. 2002
  • Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction..  23:550-557. 2002
  • Early invasive strategy for acute coronary syndromes without persistent ST-segment elevation: has the time come for 'drive-through' angiography?.  23:191-194. 2002
  • Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker..  23:239-246. 2002
  • Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA..  22:2253-2261. 2001
  • ESPRIT in context: pharmacology matters!.  22:1965-1967. 2001
  • Baseline characteristics that identify patients at high risk of death following myocardial infarction. Preliminary findings from the ALIVE trial.  22:700-700. 2001
  • Body mass index remains a significant predictor of outcome after percutaneous coronary interventions in the era of IIbIIIa inhibition.  22:524-524. 2001
  • Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study..  22:1601-1612. 2001
  • Eptifibatide (Integrilin (R)) in coronary stent implantation: long-term results of the ESPRIT trial.  22:121-121. 2001
  • Genetic variation in human Stromelysin-1 and Gelatinase B genes and acute coronary syndromes in young males.  22:164-164. 2001
  • Increased rates of stent thrombosis among patients with acute coronary syndromes: insights from two large oral IIb/IIIa antagonist trials.  22:385-385. 2001
  • Low heart rate variability (triangular index method) predicts mortality independent of beta-blocker usage, LVEF, and other factors: ALIVE trial early findings.  22:701-701. 2001
  • Pharmacokinetic and pharmacodynamic responses of the novel factor Xa inhibitor DX-9065a: results from the Xa neutralization for atherosclerotic disease understanding (XaNADU) IB trial.  22:664-+. 2001
  • The ALIVE study: heart rate variability prospectively identifies patients at high risk of death after myocardial infarction.  22:696-+. 2001
  • Aortic stiffness and calcification..  22:181. 2001
  • Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial..  21:1967-1978. 2000
  • Lack of progress in cardiogenic shock: lessons from the GUSTO trials..  21:1928-1936. 2000
  • Reperfusion synergism: will it be both sustained and safe?.  21:1913-1916. 2000
  • Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators..  21:1750-1758. 2000
  • Electron beam computed tomography: on its way into mainstream cardiology?.  21:1556-1557. 2000
  • Inter-regional differences in acute coronary syndrome trials..  21:1397-1399. 2000
  • Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction..  21:1502-1513. 2000
  • National and regional registries: what good are they?.  21:1401-1403. 2000
  • Educational level and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.  21:223-223. 2000
  • Social isolation and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.  21:213-213. 2000
  • The level of platelet inhibition maintained with a GPIIb/IIIa inhibitor following coronary intervention is strongly associated with the risk of a post-procedural MACE: results of the GOLD study.  21:145-145. 2000
  • Use of a near-patient, whole blood, multi-marker strategy (MMS) for evaluation of patients with chest pain: Results of the CHECKMATE study.  21:19-19. 2000
  • Troponins in pericarditis: implications for diagnosis and management of chest pains patients..  21:798-800. 2000
  • American College of Cardiology/ European Society of Cardiology international study of angiographic data compression phase I. The effects of lossy data compression on recognition of diagnostic features in digital coronary angiography..  21:668-678. 2000
  • Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT..  21:371-381. 2000
  • Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry..  20:1182-1190. 1999
  • Minimal myocardial damage during coronary intervention is associated with impaired outcome..  20:1112-1119. 1999
  • Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries..  20:128-135. 1999
  • Improved outlook for patients with acute myocardial infarction: an interim progress report..  19:1416-1418. 1998
  • Mechanism of protective effects of ACE inhibition on coronary artery disease..  19 Suppl J:J2-J6. 1998
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes..  19 Suppl D:D22-D30. 1998
  • International roundtable on Use of GP IIb/IIIa inhibitors in coronary syndromes: State of the art, Davos, Switzerland, 15-16 February 1997: Foreward.  19. 1998
  • The GUSTO trial and the open artery theory..  18 Suppl F:F2-10. 1997
  • Nebulized prostacyclin for pulmonary hypertension: a step in the right direction..  18:1364-1365. 1997
  • Selection of reperfusion therapy for individual patients with evolving myocardial infarction..  18:1371-1381. 1997
  • Predictors of outcome of reperfusion therapy..  18:728-735. 1997
  • Pragmatic and mechanistic trials..  18:367-370. 1997
  • The rationale for thrombolytic therapy..  17 Suppl E:2-8. 1996
  • Differential expression of angiotensin receptor subtypes in the myocardium: a hypothesis..  17:978-980. 1996
  • Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial..  17:689-698. 1996
  • Serum myoglobin for the early non-invasive detection of coronary reperfusion in patients with acute myocardial infarction..  17:399-406. 1996
  • Erratum: Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial (European Heart Journal (1996) 17 (689-698)).  17:1451. 1996
  • An overview of the results of the EPIC trial..  16 Suppl L:43-49. 1995
  • Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor..  16 Suppl L:50-55. 1995
  • Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries..  16:1024-1026. 1995
  • Impact of infarct artery patency on the relationship between electrocardiographic and ventriculographic evidence of acute myocardial ischaemia..  15:1356-1361. 1994
  • Extracellular lipid deposition in atherosclerosis..  11 Suppl E:20-28. 1990
  • Emerging role of the tissue renin-angiotensin systems in congestive heart failure..  11 Suppl B:65-71. 1990
  • In vitro analysis of jets by Doppler colour flow imaging: the importance of time to maximum jet area..  11:361-367. 1990
  • Left ventricular outflow acceleration in dilated cardiomyopathy its relationship with intrinsic ventricular load dynamics.  11:427-427. 1990
  • New interventional technology for the management of multivessel coronary artery disease..  10 Suppl H:52-56. 1989
  • Heart rate and metabolic response to competitive squash in veteran players: identification of risk factors for sudden cardiac death..  10:1029-1035. 1989
  • Two-dimensional echocardiography in arrhythmogenic right ventricular dysplasia..  10 Suppl D:22-26. 1989
  • Vascular and renal prostaglandins as counter-regulatory systems in heart failure..  9 Suppl H:15-19. 1988
  • Spontaneously healing infective endocarditis: An unrecognized phenomenon?.  8:327-330. 1987
  • Guidelines for exercise therapy of the elderly after myocardial infarction..  5 Suppl E:121-123. 1984
  • The value of early out-patient cardiac exercise programmes for the elderly in comparison with other selected age groups..  5 Suppl E:113-115. 1984
  • Imaging approach to the assessment of cardiomyopathies using delayed enhancement cardiovascular magnetic resonance: reply.  26:2602-2602.
  • Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach 2020
  • Combination of fondaparinux with radial access is associated with low rates of in-hospital MACE and major bleeding events in patients with acute coronary syndrome 2020
  • Impact of treatment strategies for AF on the progression and regression of AF type in the CABANA trial 2020
  • Incidence and risk of short episodes of atrial fibrillation detected with 14 days of continuous electrocardiographic monitoring 2020
  • Pharmacokinetics of apixaban in patients with end stage renal disease on hemodialysis and atrial fibrillation: results from the RENAL-AF trial 2020
  • Safety and efficacy of antithrombotic therapy according to stroke and bleeding risk in patients with atrial fibrillation and acute coronary syndrome or PCI: insights from AUGUSTUS 2020
  • Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE 2019
  • Association of ceramide and phospholipid levels and cardiovascular events in stable coronary heart disease: findings from the STABILITY Biomarkers substudy 2019
  • Baseline characteristics, healthcare resource use and clinical outcomes of stable post-myocardial infarction patients with diabetes: insights from the global prospective TIGRIS study 2019
  • Effect of hypertension and systolic blood pressure on cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial 2019
  • Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy 2019
  • Impact of AF type on the outcome of atrial fibrillation ablation: insights from the CABANA trial 2019
  • Impact of different estimates of renal function on cardiovascular mortality and major bleeding in patients with atrial fibrillation on oral anticoagulation 2019
  • Lipoprotein subclasses associated with high-risk coronary atherosclerotic plaque: insights from the PROMISE clinical trial 2019
  • Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study 2019
  • Network characteristics of a hypertension referral system in western kenya 2019
  • Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study 2019
  • Outcomes of catheter ablation for atrial fibrillation based on sex: data from the cabana trial 2019
  • Patients explanations of self-care in chronic heart failure: a grounded theory analysis of qualitative data from PANACEA-HF Phase 1 2019
  • Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study 2019
  • Predictors of atrial fibrillation in patients with embolic stroke of undetermined source: an analysis of the RE-SPECT ESUS trial 2019
  • Risk of stroke in hypertensive patients with atrial fibrillation treated with oral anticoagulants 2019
  • Triple vs. double antithrombotic therapy in patients needing oral anticoagulation undergoing percutaneous coronary intervention: a meta-analysis 2019
  • Agent Orange exposure in veterans with heart failure 2018
  • Association of hepatic steatosis with adverse cardiovascular events: insights from the PROspective Multicenter Imaging Study for Evaluation of chest pain (PROMISE) trial 2018
  • Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial 2018
  • Association of renin-angiotensin system inhibition with clinical outcomes in patients undergoing transcatheter aortic valve replacement: analysis from the STS/ACC TVT Registry 2018
  • Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial 2018
  • Betrixaban compared to enoxaparin among obese acute medically ill subjects: an APEX trial subgroup analysis 2018
  • Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial 2018
  • Can biomarkers be used to predict cardiopulmonary exercise test performance in patients with chronic heart failure? 2018
  • Cardiac troponin T concentrations are lower in women than men with atrial fibrillation but have similar prognostic value regardless of sex - insights from the ARISTOTLE trial 2018
  • Characterization of major and clinically relevant non-major bleeding in the APEX trial 2018
  • Cluster analysis of cardiovascular risk phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine 2018
  • Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: insights from EXSCEL 2018
  • Elevated biomarkers are associated with increased risk of death and heart failure hospitalization in patients with atrial fibrillation: insights from the ARISTOTLE trial 2018
  • Evaluation the predictive value of PARIS score for long-term out-of-hospital events after percutaneous coronary interventions 2018
  • Faster heart rate is associated with significantly higher risk of death and hospitalization due to heart failure in patients with persistent or permanent atrial fibrillation: insights from ARISTOTLE 2018
  • LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS 2018
  • Linear ongoing risk of major cardiovascular events in a global prospective registry of high-risk patients with stable coronary disease: insights from the TIGRIS study 2018
  • Moderate to severe renal insufficiency and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial 2018
  • Novel prognostic biomarkers identified by proximity extension assay are associated with major bleeding in patients with atrial fibrillation on oral anticoagulation: insights from the ARISTOTLE trial 2018
  • Performance of a machine learning model vs. IMPROVE score for VTE prediction in acute medically ill patients: insights from the APEX trial 2018
  • Use of oral anticoagulation is less among hospitalized patients with paroxysmal compared to persistent or permanent atrial fibrillation 2018
  • A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials 2017
  • Association between the timing of surgery for complicated infective endocarditis and survival 2017
  • Clinical outcomes in patients with atrial fibrillation and echocardiographic risk factors for stroke anticoagulated with apixaban or warfarin 2017
  • Determinants of antithrombotic treatment of patients with AF: baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with AF (IMPACT-AF) 2017
  • Diabetes and cardiovascular risk in patients with symptomatic peripheral artery disease 2017
  • Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy 2017
  • INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin 2017
  • Low apolipoprotein a1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial 2017
  • Pre- and post-stroke antithrombotic therapy in atrial fibrillation patients - a Danish nation-wide registry-based study 2017
  • Relationships between cigarette smoking, infarct size, and clinical outcomes in patients undergoing primary PCI For STEMI: a patient-level pooled analysis of 10 randomized trials 2017
  • Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial 2017
  • The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial 2017
  • The occurrence of stroke and TIA in patients with peripheral artery disease and the effect of ticagrelor versus clopidogrel in EUCLID 2017
  • Ticagrelor in patients with symptomatic peripheral artery disease and prior coronary artery disease 2017
  • Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial 2017
  • Comparing novel biomarkers associated with heart failure preserved ejection fraction (HFpEF): A matched case-control analysis 2016
  • Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study 2016
  • Mechanisms and impact on cardiac mortality of right ventricular dysfunction in non-ischaemic cardiomyopathy 2016
  • Multinational ethnic variations in self-reported health status in chronic heart failure patients 2016
  • Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation 2016
  • Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial 2016
  • Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT AF) 2016
  • Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT AF) 2016
  • Plasma amino acid concentrations are independently associated with adverse outcomes in heart failure and preserved ejection fraction: prognostic utility of amino acid profiles in HFpEF 2016
  • Prognostic Utility of GDF-15 in Chronic Heart Failure: Insights From the HF-ACTION Study 2016
  • Systemic embolization in patients with atrial fibrillation: results from ROCKET AF 2016
  • The EVEREST II REALISM Continued Access Study-1 year outcomes in patients with functional mitral regurgitation reported by baseline New York Heart Association functional class 2016
  • Biomarker-based risk score for prediction of cardiovascular events in stable coronary heart disease - Experiences from the STABILITY biomarker substudy 2015
  • Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in the STABILITY trial 2015
  • Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure: insights from the ARISTOTLE trial 2015
  • Effect of ivabradine on heart rate variability in patients with stable coronary artery disease 2015
  • Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE trial 2015
  • External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation 2015
  • Hypotension in patients with acute heart failure: Insights from RELAX-AHF 2015
  • Impact of pulmonary hypertension on mortality in patients treated with nitric oxide for failure to wean following cardiothoracic surgery 2015
  • Improved survival after out-of-hospital cardiac arrest most substantial in younger patients - results from a statewide quality improvement initiative in North Carolina during 2010-2013 2015
  • Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study 2015
  • Less non-major bleeding with apixaban versus warfarin among patients with atrial fibrillation: insights from the ARISTOTLE trial 2015
  • Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem? Insights from the APPRAISE-2 trial 2015
  • Off-hours versus regular hours admission and its relation with long-term mortality of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention 2015
  • Outcomes of rivaroxaban versus warfarin in women and men with nonvalvular atrial fibrillation: results from the ROCKET AF trial 2015
  • Rivaroxaban vs. warfarin with concomitant aspirin use in patients with atrial fibrillation: findings from the ROCKET AF trial 2015
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for novel oral anticoagulant dose adjustment 2015
  • Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation 2015
  • Survival improved for men but not women, despite increased bystander CPR and first resonder defibrillation for both: results form a statewide quality improvement initiative 2015
  • The EVEREST II REALISM Continued Access study-1 year outcomes in patients with primary mitral regurgitation 2015
  • The evolution of ICD programming practice: What is the relative impact of clinical evidence on clinical practice? 2015
  • Treatment consistency across levels of baseline renal function with rivaroxaban compared with warfarin: insights from ROCKET AF 2015
  • A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score 2014
  • Digoxin use in patients with atrial fibrillation is associated with adverse cardiac outcomes: results from the ROCKET AF trial 2014
  • Efficacy and safety of ticagrelor in patients with acute coronary syndrome and heart failure - insights from the platelet inhibition and patient outcomes (PLATO) trial 2014
  • Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial 2014
  • Impact of early initiation of intravenous prostanoid therapy in patients with congenital heart disease-related pulmonary arterial hypertension 2014
  • Impact of insurance status on survival in pulmonary hypertension 2014
  • Incidence and impact of patent foramen ovale among patients with pulmonary hypertension 2014
  • Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation 2014
  • Patients with native aortic stenosis represent a high-risk subgroup in nonvalvular atrial fibrillation - Results from ROCKET AF 2014
  • Predictors of and clinical outcomes after internal mammary artery graft failure: insights from the PREVENT-IV trial 2014
  • Relationship between troponin levels and long-term outcomes in medically managed patients with non-ST-segment elevation acute coronary syndromes: insights from the TRILOGY ACS trial 2014
  • The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment 2014
  • A composite peripheral blood gene expression score has high sensitivity for obstructive coronary artery disease in a non-invasive imaging population and correlates with plaque burden and morphology by 2013
  • A systematic review of outcomes related to hybrid coronary revascularization in patients with multi-vessel coronary artery disease in the drug-eluting stent era 2013
  • ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy 2013
  • Association between type of valve prosthesis and one year mortality in IE: an analysis of 1467 patients from the International collaboration on endocarditis prospective cohort study 2013
  • International variation in management and outcomes in high-risk patients following acute coronary syndromes: results from the APPRAISE-2 trial 2013
  • Mechanical dyssynchrony defined by phase analysis from GSPECT: Does it predict all cause and cardiovascular mortality? 2013
  • Reperfusion arrhythmia bursts predict larger infarct size in STEMI patients undergoing primary percutaneous coronary intervention despite optimal epicardial and microvascular flow 2013
  • Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial 2013
  • Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE 2013
  • Ventricular arrhythmia bursts following primary percutaneous coronary intervention for acute myocardial infarction: correlations with microvascular obstruction and final infarct size using CMR 2013
  • Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial 2012
  • Baseline hemoglobin predicts post-discharge events in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial 2012
  • Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis 2012
  • Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia 2012
  • Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial 2012
  • Hemodynamic response to hypoxia in heart failure patients with high peripheral chemosensitivity 2012
  • Inadequate anticoagulant therapy during end of study transition to open-label vitamin K antagonist therapy: experience in ROCKET AF 2012
  • Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy 2012
  • Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death 2012
  • Ischemia change in heart failure patients with stable coronary artery disease is an independent predictor of death and myocardial infarction 2012
  • NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin 2012
  • New insight into mental stress induced myocardial ischemia: prevalence and demographic/clinical characteristics 2012
  • Post-operative atrial fibrillation prophylaxis in clinical practice: results from the CAPS-Care STS registry 2012
  • Predictors of augmented peripheral chemosensitivity in patients with systolic heart failure 2012
  • Racial differences in acute aortic dissection: insights from the International Registry of Acute Aortic Dissection 2012
  • Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial 2012
  • Unmasked pulmonary venous hypertension during vasodilator challenge predicts poor outcomes with medical therapy 2011
  • Acute renal failure after coronary artery bypass surgery: impact of recovery of renal function on long-term mortality 2010
  • No significant increase in the incidence of infective endocarditis following the cessation of antibiotic prophylaxis for dental procedures 2010
  • Prognostic value of Galectin-3 in chronic heart failure: results from the HF-ACTION Study 2010
  • Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the PREVENT-IV trial 2010
  • A practical, validated model for prediction of risk in chronic heart failure 2006
  • Contraindications to cardiac catheterization in non-ST-elevation acute coronary syndromes: Insights from the CRUSADE national quality improvement initiative 2006
  • Fondaparinux results in less bleeding than enoxaparin, irrespective of heparin use, for patients with acute coronary syndromes 2006
  • Low dose enoxaparin in non-ST segment elevation acute coronary syndrome, followed by antiplatelet therapy alone during subsequent percutaneous coronary intervention 2006
  • Patients with acute ST-elevation myocardial infarction and prehospital delay to presentation > 12 hours: high risk of worse outcomes and selective use of reperfusion therapies. The GRACE registry 2006
  • Racial differences in high-risk patients presenting with NSTE ACS: results from the SYNERGY trial 2006
  • Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial 2006
  • Analysis of all recurrent events is superior to the time-to-first event in assessment of drug therapy to prevent ICD therapies 2005
  • Atrial fibrillation carries similar risks in heart failure irrespective of ejection fraction-results from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) 2005
  • Bundle branch block is associated with worse clinical outcomes in heart failure, especially with reduced systolic function: evidence from the CHARM programme 2005
  • Deriving a safety index from the GRACE risk score 2005
  • Determinants of delay in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. The Global Registry of acute coronary events 2005
  • Factors precipitating heart failure hospitalisation: a novel analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme 2005
  • Female gender is an independent predictor of better outcome in chronic heart failure: results from the CHARM programme 2005
  • International and time trends in the use and characteristics of patients with acute coronary syndromes treated with clopidogrel: the global registry of acute coronary events experience 2005
  • Intravenous unfractionated heparin, patient profile, and the magnitude of thrombocytopenia are associated with heparin-induced thrombocytopenia (HIT) antibodies: insights from the CATCH registry 2005
  • Predictors of quality of life in symptomatic heart failure patients across the left ventricular ejection fraction spectrum 2005
  • The importance of resting wall motion abnormalities for the diagnostic accuracy of a multicomponent stress CMR test 2005
  • Use of insulin sensitizing agents in outpatients with congestive heart failure appears safe, and may have important clinical benefits when compared with sulfonylureas and insulin 2005
  • Women (especially younger women) with chronic heart failure are less adherent to medication: results from the CHARM program 2005
  • "Leading and lagging" hospitals: can processes of care be used to rank hospitals? 2004
  • Continuous ST-segment recovery analysis is significantly more predictive of mortality than serial static analysis after thrombolytic therapy for acute MI 2004
  • Low haemoglobin is associated with more evidence of congestion but less severe systolic dysfunction in patients with chronic heart failure 2004
  • Substantial reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials 2004
  • 2704 Understanding time to treatment in acute myocardial infarction: insights from ASSENT 3 plus 2003
  • 755 Relation of myocardial scarring to clinical risk factors for sudden death in hypertrophic cardiomyopathy 2003
  • P1022 A prospective registry of patients hospitalized for worsening heart failure: observations from the IMPACT-HF registry 2003
  • P1102 Mechanism of pexelizumabs mortality benefit in acute myocardial infarction patients treated with primary percutaneous coronary intervention 2003
  • P1627 Does infarct size measured by creatine kinase-MB predict clinical outcomes after fibrinolysis and primary percutaneous coronary intervention? 2003
  • P2848 Enoxaparin versus unfractionated heparin with tenecteplase in the elderly: combined ASSENT-3 and ASSENT-3 PLUS results 2003
  • P2856 Cumulative meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions 2003
  • P2865 Treating patients with acute coronary syndromes with aggressive anti-platelet agents in the grace registry: no observed decrease in in-hospital mortality but increased bleeding complications 2003
  • P2870 Elective percutaneous coronary intervention using anti-platelet therapy alone, without unfractionated heparin or other anti-thrombin therapy 2003
  • Cost-effectiveness of valsartan in patients not receiving angiotensin-converting enzyme inhibitors at baseline 2002
  • Effect of tenecteplase versus alteplase on platelets in patients during the first three hours after acute myocardial infarction 2002
  • How does ST-segment resolution one-hour after fibrinolysis for acute myocardial infarction predict final infarct size? Insights from ASSENT 3 2002
  • Predictors of in-hospital mortality in the global registry of acute coronary events (GRACE) 2002
  • TNK with reduced dose unfractionated heparin associated with similar efficacy and less bleeding: results from ASSENT-2 and ASSENT-3 2002
  • Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure 2001
  • Perspectives gained from large-scale thrombolytic comparative trials. 1996
  • Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers. 1995
  • Regional left ventricular diastolic properties during pacing induced ischemia in dogs with coronary stenoses 1981